New Global Consortium to Advance First-Ever Clinical Testing of the Human Hookworm Vaccine in Sub-Saharan Africa

AMSTERDAM & WASHINGTON, DC – September 26, 2013 – The HOOKVAC consortium, led by the Academic Medical Center (AMC) at the University of Amsterdam, today announced it has been awarded a grant of six million Euros from the European Commission FP7 programme to expand the Sabin Vaccine Institute Product Development Partnership’s (Sabin PDP) work to develop and test a vaccine for human hookworm, a disease that infects 600-700 million of the world’s poorest people. Under this grant, the HOOKVAC consortium, which includes partners from the European Union, United States and Africa, will begin the first clinical testing of the human hookworm vaccine in the West African nation of Gabon.

Statement by the Sabin Vaccine Institute on the 2013 G8 Lough Erne Summit

The 2013 G8 Summit in Northern Ireland concluded on June 18th with the release of the Lough Erne Communiqué. Although G8 leaders addressed important tax, trade and transparency issues to help alleviate global poverty, they failed to discuss neglected tropical diseases (NTDs), a burden that perpetuates poverty and increases inequalities.

Statement by the Sabin Vaccine Institute on the Occasion of the Organization of American States’ Resolution “Elimination of Neglected Diseases and Other Poverty-Related Infections”

Last week, the Organization of American States (OAS), the main political and social governmental forum for nations in Latin America and the Caribbean, approved a resolution supporting the control and elimination of neglected tropical diseases (NTDs) during the 43rd General Assembly in Antigua, Guatemala.

Pages